Flozination International

FLOZINATE‼️ A place to share our love for SGLT2i and evidence-based cardiorenal health #Flozination #Nephtwitter | Academic purposes, not medical advice

[Flozination International @FlozinationInt]

An 🍏 a day keeps the 👨🏽‍⚕️ away

❇️ In 1835 🇧🇪scientists discovered “phloridzin” in the bark of 🍏tree, for many years thought to be an antipyretic

❇️ In 1886 the Baron von Mering 🇩🇪 discovered its glucosuric effects and the drug was even considered DIABETOGENIC‼️

1/5

[Flozination International @FlozinationInt]

💥POLL ALERT💥

Flozins are becoming a new standard of care in cardiometabolic diseases, but…

❓Do you know where did the story of Glucose Reuptake inhibition begin❓

🔜🧵

#flozination #MedTwitter #NephTwitter

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Additive effects of dapagliflozin and finerenone on albuminuria in “non-diabetic” CKD: an open-label randomized clinical trial ca. 2024 from @CKJsocial #Nephpearls #Cardiorenal

👉🏼 https://t.co/gjQtK1b6zH

[Rafael Kramann, MD PhD @rkramann]

1/16) We are excited to share our recent paper “ADAMTS12 promotes fibrosis by restructuring extracellular matrix to enable activation of injury-responsive fibroblasts” published today @Jclinicalinvest led by @KonradHoeft and @Lars_K0ch https://t.co/3JkwsN8eZ7

[JASN_News @JASN_News]

Study found sodium-glucose cotransporter-2 inhibitors (SGLT2i) improved kidney outcomes in cohorts with heart failure, CKD, and type 2 diabetes mellitus. Effects were consistent across patients w/ different combinations of these comorbidities @javedbutler1 https://t.co/bqp1UBIRX2

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) and CKD: Are You a #Flozinator? ca. 2023 from @KidneyMed @GlomCon #Nephpearls

👉 https://t.co/mn5ayR8yqs

[HCKH_Hamburg @HCKH_Hamburg]

Hamburg-@ERA24 news: Now out @NEJM, the international collaborative study on the clinical and pathophysiological role of anti-nephrin autoantibodies in podocytopathies
https://t.co/6IruKJWuBJ
@ISGDtweets @hckh_hamburg @UKEHamburg @Tobias_B_Huber @NicolaMTomas @hengel_f

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

In patients with kidney failure on dialysis, dapagliflozin was well tolerated, was slightly dialyzable, and had non-accumulating pharmacokinetic properties ca. 2023 from @CJASN #Nephpearls #NephJC

👉 https://t.co/cTRliEV5Fe

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

RENAL LIFECYCLE Trial: Efficacy and safety of dapagliflozin 10 mg vs placebo #Nephpearls #NephJC

✅ eGFR <25
✅ Patients on dialysis with residual diuresis >500 mL/24-hour
✅ Kidney transplant recipients with an eGFR </=45

📌 PRIMARY ENDPOINT: Composite end point of kidney failure, heart failure hospitalization, or all-cause mortality by

#VisualGraphic by @deniise_am

👉https://t.co/nXoxb1fIuD

[Mike Martínez Rojas @MRMike_MD]

🚨PAPER ALERT‼️

So happy to see my PhD work finally out in @JCI_insight

Some #flozination of our own in @normaabobadilla Lab 🇲🇽

👇🏿
https://t.co/D27qJIu2ot

I’ll walk y’all briefly through this 🥰

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Which patients with CKD are candidates for SGLT2 inhibitors: Cold 🥶 Map #Nephpearls

[Flozination International @FlozinationInt]

@kidney_boy @ChristosArgyrop @brendonneuen TGF has both afferent and efferent effects, it is known that increased NaCl delivery to the MD increases Adenosine release and, in the efferent arteriole, A2 receptors induce vasodilation… apparently this is a milder effect compared to the afferent constriction, but still

[Markus Rinschen @mrins01]

Our study on metabolic communication by SGLT2 inhibition is now online @circaha. We describe how SGLT2 inhibitors provide metabolic kidney and heart protection, by systematic analysis of early and off-target effects of the drug across metabolic organs in the same mice.

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

RENAL LIFECYCLE Trial: Efficacy and safety of dapagliflozin 10 mg vs placebo #Nephpearls
✅ eGFR <25
✅ Patients on dialysis with residual diuresis >500 ml/24-hour
✅ Kidney transplant recipients with an eGFR </=45

📌 PRIMARY ENDPOINT: Composite end point of kidney failure, heart failure hospitalization, or all-cause mortality

#VisualGraphic by @deniise_am

👉 https://t.co/BKKRwUmxla

[Flozination International @FlozinationInt]

@DraNefrona Urgen cohortes prospectivas, marcadores pronósticos tempranos y terapias dirigidas contra la transición a ERC

[Brendon Neuen @brendonneuen]

Time to implement the #4pillars of “kidney GDMT”

- RAS blockade
- SGLT2i
- ns-MRA
- GLP-1 RA

Lifetime cardiovascular, kidney &amp; mortality benefits of combination therapy in people with diabetes with albuminuria

Now #openaccess in @CircAHA for #AHA23

https://t.co/yRLSRlVujH

[Flozination International @FlozinationInt]

#flozination leads to Acute renal success??

How low of eGFR decline is TOO low??

👇🏿

[Flozination International @FlozinationInt]

🤓 #kw2023 #flozinate

“After dark times in nephrology with many failed RCT… the ☀️ at the end of the tunnel, with such robust data in CKD and CVD… ASK WHO SHOULD NOT BE PRESCRIBED WITH SGLT2i”
@scoca1 👏🏾

👨‍🏫👩‍🏫 What’s new with SGLT2i in 2023

#kidneyweek #nephtwitter

[Flozination International @FlozinationInt]

Interesting thing, mainly in T2D:

🔆SGLT2i work w/ or w/o RAASi
🔆GLP1A, Finerenone, and ETAi work w/ or w/o SGLT2 i

Updates on recommendations and 🔜RCT

#flozinate #nephpearls

[Pablo Galindo @galindozip]

They have a very good point

How renal is the kidney? - The Lancet https://t.co/0pS8yGsoEl

[Flozination International @FlozinationInt]

Acute Renal Success 🤓

[ASN Kidney360 @ASNKidney360]

SGLT2 inhibitors are often withheld during AKI due to concerns about worsening GFR. This study found in adults experiencing acute heart failure-associated AKI, exposure to SGLT2 inhibitors was linked to decreased mortality https://t.co/Z7bpK02dSS

@FJSinha @dmoledina @Nephronette